150 related articles for article (PubMed ID: 34132691)
1. Transcriptomic Profiling Identifies an Exosomal microRNA Signature for Predicting Recurrence Following Surgery in Patients With Pancreatic Ductal Adenocarcinoma.
Nishiwada S; Cui Y; Sho M; Jun E; Akahori T; Nakamura K; Sonohara F; Yamada S; Fujii T; Han IW; Tsai S; Kodera Y; Park JO; Von Hoff D; Kim SC; Li W; Goel A
Ann Surg; 2022 Dec; 276(6):e876-e885. PubMed ID: 34132691
[TBL] [Abstract][Full Text] [Related]
2. A MicroRNA Signature Identifies Pancreatic Ductal Adenocarcinoma Patients at Risk for Lymph Node Metastases.
Nishiwada S; Sho M; Banwait JK; Yamamura K; Akahori T; Nakamura K; Baba H; Goel A
Gastroenterology; 2020 Aug; 159(2):562-574. PubMed ID: 32376411
[TBL] [Abstract][Full Text] [Related]
3. An Exosome-based Transcriptomic Signature for Noninvasive, Early Detection of Patients With Pancreatic Ductal Adenocarcinoma: A Multicenter Cohort Study.
Nakamura K; Zhu Z; Roy S; Jun E; Han H; Munoz RM; Nishiwada S; Sharma G; Cridebring D; Zenhausern F; Kim S; Roe DJ; Darabi S; Han IW; Evans DB; Yamada S; Demeure MJ; Becerra C; Celinski SA; Borazanci E; Tsai S; Kodera Y; Park JO; Bolton JS; Wang X; Kim SC; Von Hoff D; Goel A
Gastroenterology; 2022 Nov; 163(5):1252-1266.e2. PubMed ID: 35850192
[TBL] [Abstract][Full Text] [Related]
4. Identification of Serum miRNA Signature and Establishment of a Nomogram for Risk Stratification in Patients With Pancreatic Ductal Adenocarcinoma.
Kandimalla R; Shimura T; Mallik S; Sonohara F; Tsai S; Evans DB; Kim SC; Baba H; Kodera Y; Von Hoff D; Chen X; Goel A
Ann Surg; 2022 Jan; 275(1):e229-e237. PubMed ID: 32398486
[TBL] [Abstract][Full Text] [Related]
5. Identification of Nectin Family Interactive Gene Panel and Stratification of Clinical Outcomes in Patients with Pancreatic Cancer.
Imazu Y; Nishiwada S; Yasuda S; Nagai M; Nakamura K; Matsuo Y; Terai T; Yoshida C; Kohara Y; Sho M
J Am Coll Surg; 2023 Nov; 237(5):719-730. PubMed ID: 37503950
[TBL] [Abstract][Full Text] [Related]
6. Plasma extracellular vesicle messenger RNA profiling identifies prognostic EV signature for non-invasive risk stratification for survival prediction of patients with pancreatic ductal adenocarcinoma.
Han Y; Drobisch P; Krüger A; William D; Grützmann K; Böthig L; Polster H; Seifert L; Seifert AM; Distler M; Pecqueux M; Riediger C; Plodeck V; Nebelung H; Weber GF; Pilarsky C; Kahlert U; Hinz U; Roth S; Hackert T; Weitz J; Wong FC; Kahlert C
J Hematol Oncol; 2023 Feb; 16(1):7. PubMed ID: 36737824
[TBL] [Abstract][Full Text] [Related]
7. Usefulness of exosome-encapsulated microRNA-451a as a minimally invasive biomarker for prediction of recurrence and prognosis in pancreatic ductal adenocarcinoma.
Takahasi K; Iinuma H; Wada K; Minezaki S; Kawamura S; Kainuma M; Ikeda Y; Shibuya M; Miura F; Sano K
J Hepatobiliary Pancreat Sci; 2018 Feb; 25(2):155-161. PubMed ID: 29130611
[TBL] [Abstract][Full Text] [Related]
8. A pilot study to develop a diagnostic test for pancreatic ductal adenocarcinoma based on differential expression of select miRNA in plasma and bile.
Cote GA; Gore AJ; McElyea SD; Heathers LE; Xu H; Sherman S; Korc M
Am J Gastroenterol; 2014 Dec; 109(12):1942-52. PubMed ID: 25350767
[TBL] [Abstract][Full Text] [Related]
9. Candidate microRNA biomarkers of pancreatic ductal adenocarcinoma: meta-analysis, experimental validation and clinical significance.
Ma MZ; Kong X; Weng MZ; Cheng K; Gong W; Quan ZW; Peng CH
J Exp Clin Cancer Res; 2013 Sep; 32(1):71. PubMed ID: 24289824
[TBL] [Abstract][Full Text] [Related]
10. Genome-wide Discovery and Identification of a Novel miRNA Signature for Recurrence Prediction in Stage II and III Colorectal Cancer.
Kandimalla R; Gao F; Matsuyama T; Ishikawa T; Uetake H; Takahashi N; Yamada Y; Becerra C; Kopetz S; Wang X; Goel A
Clin Cancer Res; 2018 Aug; 24(16):3867-3877. PubMed ID: 29514841
[No Abstract] [Full Text] [Related]
11. A transcriptomic signature that predicts cancer recurrence after hepatectomy in patients with colorectal liver metastases.
Wada Y; Shimada M; Morine Y; Ikemoto T; Saito Y; Baba H; Mori M; Goel A
Eur J Cancer; 2022 Mar; 163():66-76. PubMed ID: 35042069
[TBL] [Abstract][Full Text] [Related]
12. Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer.
Hwang JH; Voortman J; Giovannetti E; Steinberg SM; Leon LG; Kim YT; Funel N; Park JK; Kim MA; Kang GH; Kim SW; Del Chiaro M; Peters GJ; Giaccone G
PLoS One; 2010 May; 5(5):e10630. PubMed ID: 20498843
[TBL] [Abstract][Full Text] [Related]
13. A 15-Gene Immune, Stromal, and Proliferation Gene Signature that Significantly Associates with Poor Survival in Patients with Pancreatic Ductal Adenocarcinoma.
Kandimalla R; Tomihara H; Banwait JK; Yamamura K; Singh G; Baba H; Goel A
Clin Cancer Res; 2020 Jul; 26(14):3641-3648. PubMed ID: 32234757
[TBL] [Abstract][Full Text] [Related]
14. Identification and Validation of a Biomarker Signature in Patients With Resectable Pancreatic Cancer via Genome-Wide Screening for Functional Genetic Variants.
Dimitrakopoulos C; Vrugt B; Flury R; Schraml P; Knippschild U; Wild P; Hoerstrup S; Henne-Bruns D; Wuerl P; Graf R; Breitenstein S; Bond G; Beerenwinkel N; Grochola LF
JAMA Surg; 2019 Jun; 154(6):e190484. PubMed ID: 30942874
[TBL] [Abstract][Full Text] [Related]
15. Pancreatic cancer survival analysis defines a signature that predicts outcome.
Raman P; Maddipati R; Lim KH; Tozeren A
PLoS One; 2018; 13(8):e0201751. PubMed ID: 30092011
[TBL] [Abstract][Full Text] [Related]
16. A gene expression signature for predicting response to neoadjuvant chemoradiotherapy in pancreatic ductal adenocarcinoma.
Nishiwada S; Sho M; Cui Y; Yamamura K; Akahori T; Nakagawa K; Nagai M; Nakamura K; Takagi T; Ikeda N; Li W; Baba H; Goel A
Int J Cancer; 2021 Feb; 148(3):769-779. PubMed ID: 32895958
[TBL] [Abstract][Full Text] [Related]
17. Identification of an Immune-Related BAT Signature for Predicting Adjuvant Chemotherapy Response and Overall Survival in Patients with Resected Ductal Adenocarcinoma of the Pancreas.
Pu N; Chen Q; Yin H; Zhang J; Zhao G; Habib JR; Chen J; Yu J; Lou W; Wu W
J Gastrointest Surg; 2022 Apr; 26(4):869-886. PubMed ID: 35059985
[TBL] [Abstract][Full Text] [Related]
18. Analysis of Blood Plasma MicroRNAs to Enable Identification of Patients with Pancreatic Ductal Adenocarcinoma Who Will Benefit from Surgical Resection.
Gablo N. A; Procházka V; Hlavsa J; Kiss I; Srovnal J; Kala Z; Slabý O
Klin Onkol; 2019; 32(Suppl 1):174-176. PubMed ID: 31064193
[TBL] [Abstract][Full Text] [Related]
19. A Transcriptomic Signature for Risk-Stratification and Recurrence Prediction in Intrahepatic Cholangiocarcinoma.
Wada Y; Shimada M; Yamamura K; Toshima T; Banwait JK; Morine Y; Ikemoto T; Saito Y; Baba H; Mori M; Goel A
Hepatology; 2021 Sep; 74(3):1371-1383. PubMed ID: 33725402
[TBL] [Abstract][Full Text] [Related]
20. Global microRNA expression profiling of microdissected tissues identifies miR-135b as a novel biomarker for pancreatic ductal adenocarcinoma.
Munding JB; Adai AT; Maghnouj A; Urbanik A; Zöllner H; Liffers ST; Chromik AM; Uhl W; Szafranska-Schwarzbach AE; Tannapfel A; Hahn SA
Int J Cancer; 2012 Jul; 131(2):E86-95. PubMed ID: 21953293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]